Midodrine improves clinical and economic outcomes in patients with septic shock: a randomized controlled clinical trial.

Abstract

Prolonged use of intravenous (IV) vasopressors in patients with septic shock can lead to deleterious effects. This study assessed the impact of midodrine administration on weaning off IV vasopressors and its economic value. It is a prospective randomized controlled study of 60 resuscitated patients with septic shock who demonstrated clinical stability on low-dose IV vasopressors for at least 24h. Participants were randomized into two groups: norepinephrine (IV norepinephrine) and midodrine (IV norepinephrine + oral midodrine 10mg thrice a day). A cost comparison was applied based on the outcomes of both groups. The median duration of norepinephrine administration in the midodrine and norepinephrine groups was 4 and 6days, respectively (p = 0.001). Norepinephrine weaning time was significantly less in the midodrine versus norepinephrine groups (26 and 78.5h, respectively; p < 0.001). Mortality was 43.3% versus 73.3% in the midodrine and norepinephrine groups, respectively (p = 0.018). The mean length of stay was comparable in the two groups. The midodrine group showed cost-saving results versus the norepinephrine group. The use of midodrine in septic shock patients significantly reduced IV norepinephrine duration, weaning period during the septic shock recovery phase, and mortality. Thus, the use of midodrine is dominant with less cost, better outcome and a cost-saving option in terms of budget impact analysis. This study was registered at clinicaltrials.gov (NCT 03,911,817) on April 11, 2019.